Principal Investigator
Jay Spiegel
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221022
Clinical Trial Summary
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (δ) T Cells in Adults with B Cell Malignancies
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647